vigabatrin has been researched along with Dyskinesia, Drug-Induced in 17 studies
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 7.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "Vigabatrin was specifically designed to enhance gamma-aminobutyric acid (GABA) function in the CNS." | 3.77 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. ( Grant, SM; Heel, RC, 1991) |
| "Acute and chronic administration of vigabatrin, a selective inactivator of GABA-T, suppresses haloperidol-induced dyskinesias at low doses without preventing the enhancement of striatal dopamine D2 receptor density or the development of vacuous chewing movements." | 1.29 | Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin. ( Elands, J; Gobaille, S; Grauffel, C; Knödgen, B; Moran, P; Sarhan, S; Seiler, N; van den Buuse, M, 1995) |
| "Tetrahydroisoxazolopyridinol (THIP), a GABA receptor agonist, gamma-acetylenic-GABA(GAG) and gamma-vinyl-GABA(GVG), two GABA transaminase inhibitors were given in single parenteral doses to three Cebus apella monkeys with persistent dyskinetic movements induced by earlier long-term administration of haloperidol." | 1.27 | GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias. ( Andersson, U; Häggström, JE, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (76.47) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, LR | 1 |
| Bosemani, T | 1 |
| Smith-Hicks, CL | 1 |
| Gale, K | 1 |
| Casu, M | 1 |
| Tamminga, CA | 3 |
| Thaker, GK | 3 |
| Ferraro, TN | 2 |
| Hare, TA | 3 |
| Korsgaard, S | 1 |
| Casey, DE | 1 |
| Gerlach, J | 1 |
| Lambert, PA | 2 |
| Cantiniaux, P | 2 |
| Chabannes, JP | 2 |
| Tell, GP | 2 |
| Schechter, PJ | 2 |
| Koch-Weser, J | 2 |
| Danion, JM | 1 |
| Singer, L | 1 |
| Tell, G | 1 |
| Schechter, P | 1 |
| Seiler, N | 1 |
| Grauffel, C | 1 |
| Elands, J | 1 |
| van den Buuse, M | 1 |
| Knödgen, B | 1 |
| Sarhan, S | 1 |
| Moran, P | 1 |
| Gobaille, S | 1 |
| Turjanski, N | 1 |
| Lees, AJ | 1 |
| Grant, SM | 1 |
| Heel, RC | 1 |
| Andersson, U | 1 |
| Häggström, JE | 1 |
| Hammond, EJ | 2 |
| Wilder, BJ | 2 |
| Alphs, LD | 1 |
| Lafferman, J | 1 |
| Gaio, JM | 1 |
| Pollak, P | 1 |
| Hommel, M | 1 |
| Perret, J | 1 |
| Stahl, SM | 1 |
| Thornton, JE | 1 |
| Simpson, ML | 1 |
| Berger, PA | 1 |
| Napoliello, MJ | 1 |
5 reviews available for vigabatrin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
Topics: 4-Aminobutyrate Transaminase; Afferent Pathways; Aminocaproates; Animals; Basal Ganglia; Behavior, A | 1981 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine; | 1985 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
7 trials available for vigabatrin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
GABA agonist treatment improves tardive dyskinesia.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Clinical Trials as Topic; Double-Blind Method; Dyskine | 1983 |
[Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics].
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Antipsychotic Agents; Clinical Trials as | 1982 |
GABA system: clinical research and treatment of tardive dyskinesia.
Topics: Alkynes; Aminocaproates; Benzodiazepines; Clinical Trials as Topic; Corpus Striatum; Dopamine; Dyski | 1983 |
[Gamma-vinyl GABA and tardive dyskinesia: a single-blind study versus placebo].
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aged; Aminocaproates; Drug Evaluation; Dyskinesia, | 1984 |
Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Animals; Ataxia; Child; Dyskinesia, Drug- | 1991 |
Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
Topics: Adult; Aminocaproates; Brain; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induce | 1987 |
Gamma-vinyl GABA: a new antiepileptic drug.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain Chemistry | 1985 |
8 other studies available for vigabatrin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Neuroimaging Abnormalities in a Child With Infantile Spasms on High-Dose Vigabatrin.
Topics: Developmental Disabilities; Down Syndrome; Dyskinesia, Drug-Induced; Female; GABA Agents; Humans; In | 2017 |
Effect of gamma-vinyl GABA in tardive dyskinesia.
Topics: Adult; Aged; Aminocaproates; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Male; Middle Ag | 1983 |
Effects of gamma-vinyl GABA.
Topics: Aminocaproates; Dyskinesia, Drug-Induced; Humans; Vigabatrin | 1981 |
Suppression of haloperidol-induced oral dyskinesias in rats by vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Body Weight; Brain; Dyskinesia, Drug-Induced | 1995 |
Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: 4-Aminobutyrate Transaminase; Adult; Aged; Aminocaproates; Chorea; Dose-Response Relationship, Drug; | 1992 |
GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias.
Topics: 4-Aminobutyrate Transaminase; Alkynes; Aminocaproates; Animals; Antipsychotic Agents; Cebus; Dyskine | 1988 |
Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia.
Topics: Aged; Aminocaproates; Carnosine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Mental D | 1987 |
Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders.
Topics: Adult; Aged; Aminocaproates; Confusion; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; H | 1985 |